1α,25(OH)2D3 Analog, MART-10, Inhibits Neuroendocrine Tumor Cell Metastasis After VEGF-A Stimulation

Chiang, Kun‐Chun; Yeh, Chun‐Nan; Pang, Jong‐Hwei S.; Yeh, Ta‐Sen; Chen, Liwei; Kuo, Sheng‐Fong; Takano, Masashi; Chen, Thomas; Kittaka, Atsushi; Hsieh, Po-Jen; Juang, Horng‐Heng

doi:10.21873/anticanres.12072

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An in vitro study using RIN-m cells, a rat insulinoma cell line expressing VDR, demonstrated that the exposure to 1α,25-dihydroxyvitamin D3 [1α,25(OH) 2 D 3 ] or MART-10, a 1α,25(OH) 2 D 3 analog, inhibits cell growth by induction of cell-cycle arrest at G0/G1 phase and apoptosis [103]. The same group also demonstrated that both MART-10 and 1α,25(OH) 2 D 3 effectively inhibited VEGF-induced metastatic potential of RIN-m cells through reducing the epithelial-mesenchymal transition and F-actin, which plays a role in cell migration and invasion [104]. These studies suggest that vitamin D and its analogs might represent a promising regimen for the treatment of NET patients.…”

Section: Vitamin D In Gep-netmentioning

confidence: 99%

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Altieri¹,

Dato

Modica

et al. 2020

Nutrients

View full text Add to dashboard Cite

Patients affected by gastroenteropancreatic–neuroendocrine tumors (GEP–NETs) have an increased risk of developing osteopenia and osteoporosis, as several factors impact on bone metabolism in these patients. In fact, besides the direct effect of bone metastasis, bone health can be affected by hormone hypersecretion (including serotonin, cortisol, and parathyroid hormone-related protein), specific microRNAs, nutritional status (which in turn could be affected by medical and surgical treatments), and vitamin D deficiency. In patients with multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome associated with NET occurrence, bone damage may carry other consequences. Osteoporosis may negatively impact on the quality of life of these patients and can increment the cost of medical care since these patients usually live with their disease for a long time. However, recommendations suggesting screening to assess bone health in GEP–NET patients are missing. The aim of this review is to critically analyze evidence on the mechanisms that could have a potential impact on bone health in patients affected by GEP–NET, focusing on vitamin D and its role in GEP–NET, as well as on factors associated with MEN1 that could have an impact on bone homeostasis.

show abstract

Section: Vitamin D In Gep-netmentioning

confidence: 99%

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Altieri¹,

Dato

Modica

et al. 2020

Nutrients

View full text Add to dashboard Cite

show abstract

Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors

et al. 2021

View full text Add to dashboard Cite

Effects of Vitamin D Analogs Alfacalcidol and Calcitriol on Cell Proliferation and Migration of HEC1A Endometrial Adenocarcinoma Cells

Duman

Tiftik

Ün

2020

Nutrition and Cancer

View full text Add to dashboard Cite

1α,25(OH)2D3 Analog, MART-10, Inhibits Neuroendocrine Tumor Cell Metastasis After VEGF-A Stimulation

Abstract: Our data indicate that MART-10 could be deemed a promising drug for PanNET treatment.

Cited by 3 publications

References 27 publications

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors

Effects of Vitamin D Analogs Alfacalcidol and Calcitriol on Cell Proliferation and Migration of HEC1A Endometrial Adenocarcinoma Cells

Contact Info

Product

Resources

About